Patents by Inventor Geoffrey T. Yarranton

Geoffrey T. Yarranton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION ANTIBIOTIC AND ANTIBODY THERAPY FOR THE TREATMENT OF PSEUDOMONAS AERUGINOSA INFECTION
    Publication number: 20100272736
    Abstract: The present invention provides improved pharmaceutical compositions and methods of treating or preventing development of bacteremia associated with Pseudomonas aeruginosa infections, where the method comprises administering an antibiotic and an anti-PcrV antibody.
    Type: Application
    Filed: February 4, 2010
    Publication date: October 28, 2010
    Applicants: KaloBios Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Mark Baer, Christopher R. Bebbington, Geoffrey T. Yarranton, Susan Lynch, Yuanlin Song
  • Tripeptide prodrug compounds
    Patent number: 7816317
    Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making and using the prodrug compounds.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: October 19, 2010
    Assignee: Medarex, Inc.
    Inventors: Christopher R. Bebbington, Vincent Dubois, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey T. Yarranton
  • Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3
    Publication number: 20100226930
    Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.
    Type: Application
    Filed: March 5, 2010
    Publication date: September 9, 2010
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
  • METHODS OF TREATING DEMENTIA USING A GM-CSF ANTAGONIST
    Publication number: 20100215650
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody and pharmaceutical compositions comprising such antagonists.
    Type: Application
    Filed: February 11, 2010
    Publication date: August 26, 2010
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
  • Prodrug compounds with isoleucine
    Patent number: 7696313
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide having an isoleucine residue, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by an enzyme associated with the target cell. Methods of making and using the compounds are also disclosed.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: April 13, 2010
    Assignee: Medarex, Inc.
    Inventors: Lesley B. Pickford, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Geoffrey T. Yarranton
  • ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
    Publication number: 20090274706
    Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Application
    Filed: April 28, 2009
    Publication date: November 5, 2009
    Applicant: Kalobios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton
  • Neutralization of GM-CSF for the Treatment of Heart Failure
    Publication number: 20090263387
    Abstract: This invention relates to methods of treating a patient suffering from heart failure, or a patient at risk for heart failure, using a GM-CSF antagonist.
    Type: Application
    Filed: April 7, 2009
    Publication date: October 22, 2009
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton
  • Antibodies to the PcrV Antigen of Pseudomonas aeruginosa
    Publication number: 20090191186
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Application
    Filed: December 1, 2008
    Publication date: July 30, 2009
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • Methods of Treating Bone-Loss Disorders Using a GM-CSF Antagonist
    Publication number: 20090181020
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of bone loss disorders, such as osteopenia. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, to a patient that has a bone loss disorder and pharmaceutical compositions comprising such antagonists.
    Type: Application
    Filed: January 15, 2009
    Publication date: July 16, 2009
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. BEBBINGTON, Geoffrey T. Yarranton
  • Enzyme-cleavable prodrug compounds
    Publication number: 20090110753
    Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with prodrugs of the invention.
    Type: Application
    Filed: August 14, 2008
    Publication date: April 30, 2009
    Applicant: MEDAREX, INC.
    Inventors: Vincent Dubois, Anne Marie Fernandez, Sanjeev Gangwar, Evan Lewis, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey T. Yarranton
  • EphA3 Antibodies for the Treatment of Solid Tumors
    Publication number: 20080286272
    Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors.
    Type: Application
    Filed: March 10, 2008
    Publication date: November 20, 2008
    Applicants: KaloBios Pharmaceuticals, Inc., Ludwig Institute for Cancer Research, Monash University
    Inventors: Martin Lackmann, Andrew Mark Scott, Christopher R. Bebbington, Geoffrey T. Yarranton, Carmelina Murone, Catherine To
  • Prodrug compounds with isoleucine
    Publication number: 20080255248
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide having an isoleucine residue, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by an enzyme associated with the target cell. Methods of making and using the compounds are also disclosed.
    Type: Application
    Filed: January 16, 2008
    Publication date: October 16, 2008
    Applicant: MEDAREX, INC.
    Inventors: Lesley B. Pickford, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Geoffrey T. Yarranton
  • Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
    Publication number: 20080206241
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of chronic inflammatory disease, such as rheumatoid arthritis. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, and an anti-folate compounds, e.g., methotrexate, to a patient that has RA and pharmaceutical compositions comprising such antagonists.
    Type: Application
    Filed: November 21, 2007
    Publication date: August 28, 2008
    Applicant: KaloBios Pharmaceuticals Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton
  • METHODS OF TREATING IDIOPATHIC THROMBOCYTOPENIA PURPURA USING A GM-CSF ANTAGONIST
    Publication number: 20080171038
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of Idiopathic Thrombocytopenia Purpura (ITP). Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, to a patient that has ITP and pharmaceutical compositions comprising such antagonists.
    Type: Application
    Filed: November 8, 2007
    Publication date: July 17, 2008
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton
  • Prodrug compounds with isoleucine
    Patent number: 7329507
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide having an isoleucine residue, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by an enzyme associated with the target cell. Methods of making and using the compounds are also disclosed.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: February 12, 2008
    Assignee: Medarex, Inc.
    Inventors: Lesley B. Pickford, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Geoffrey T. Yarranton
  • Tripeptide prodrug compounds
    Patent number: 7214663
    Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making and using the prodrug compounds.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: May 8, 2007
    Assignee: Medarex, Inc.
    Inventors: Christopher R. Bebbington, Vincent Dubois, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey T. Yarranton
  • Cytotoxic agents
    Patent number: 7129261
    Abstract: The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the linker arms of the invention.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: October 31, 2006
    Assignee: Medarex, Inc.
    Inventors: Howard P. Ng, Danny P.C. McGee, Oliver L. Saunders, Valeri Martichonok, Guoxian Wu, Zhihong Li, Geoffrey T. Yarranton
  • Prodrug compounds with an isoleucine
    Patent number: 7115573
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide having an isoleucine residue, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by an enzyme associated with the target cell. Methods of making and using the compounds are also disclosed.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: October 3, 2006
    Assignee: Medarex, Inc.
    Inventors: Lesley B. Pickford, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Geoffrey T. Yarranton
  • Prodrug compounds with an oligopeptide having an isoluecine residue
    Publication number: 20040039160
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide having an isoleucine residue, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by an enzyme associated with the target cell. Methods of making and using the compounds are also disclosed.
    Type: Application
    Filed: December 13, 2002
    Publication date: February 26, 2004
    Inventors: Lesley B. Pickford, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Geoffrey T. Yarranton
  • Tripeptide prodrug compounds
    Publication number: 20030181359
    Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making and using the prodrug compounds.
    Type: Application
    Filed: December 13, 2002
    Publication date: September 25, 2003
    Inventors: Christopher R. Bebbington, Vincent Dubois, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey T. Yarranton